Summary of COVID-19 MIB-626 studies
Hide extended summaries
39 patient MIB-626 late treatment RCT: 156% higher mortality (p=1) and 18% improved recovery (p=0.71).
RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised blood NAD+ levels, but this did not result in any significant difference in the primary endpoint (serum creatinine). Furthermore, there were no significant differences in secondary endpoints, including other markers of AKI (cystatin C, NGAL, KIM-1), inflammation (CRP, IL-6, TNFa), or overall clinical disease severity.
Jun 2025, FASEB BioAdvances, https://faseb.onlinelibrary.wiley.com/doi/10.1096/fba.2025-00014, https://c19p.org/pencina
39 patient MIB-626 late treatment RCT: 156% higher mortality (p=1) and 18% improved recovery (p=0.71).
RCT 42 hospitalized patients with COVID-19 and acute kidney injury (AKI) showing no clinical benefit with MIB-626 (β-nicotinamide mononucleotide) treatment. The study found that 1.0g of MIB-626 twice daily safely and significantly raised blood NAD+ levels, but this did not result in any significant difference in the primary endpoint (serum creatinine). Furthermore, there were no significant differences in secondary endpoints, including other markers of AKI (cystatin C, NGAL, KIM-1), inflammation (CRP, IL-6, TNFa), or overall clinical disease severity.
Jun 2025, FASEB BioAdvances, https://faseb.onlinelibrary.wiley.com/doi/10.1096/fba.2025-00014, https://c19p.org/pencina
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.